

Fiscal Note

State of Alaska
2016 Legislative Session

Bill Version: SB 113
Fiscal Note Number: _____
() Publish Date: _____

Identifier: SB113-DCCED-CBPL-02-19-16
Title: NEW DRUGS FOR THE TERMINALLY ILL
Sponsor: WIELECHOWSKI
Requester: (S) Health and Social Services

Department: Department of Commerce, Community and
Economic Development
Appropriation: Corporations, Business and Professional
Licensing
Allocation: Corporations, Business and Professional
Licensing
OMB Component Number: 2360

Expenditures/Revenues

Note: Amounts do not include inflation unless otherwise noted below.

(Thousands of Dollars)

	FY2017 Appropriation Requested	Included in Governor's FY2017 Request	Out-Year Cost Estimates				
OPERATING EXPENDITURES	FY 2017	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
Personal Services							
Travel							
Services							
Commodities							
Capital Outlay							
Grants & Benefits							
Miscellaneous							
Total Operating	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Fund Source (Operating Only)

None							
Total	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Positions

Full-time							
Part-time							
Temporary							

Change in Revenues							
---------------------------	--	--	--	--	--	--	--

Estimated SUPPLEMENTAL (FY2016) cost: 0.0 (separate supplemental appropriation required)
(discuss reasons and fund source(s) in analysis section)

Estimated CAPITAL (FY2017) cost: 0.0 (separate capital appropriation required)
(discuss reasons and fund source(s) in analysis section)

ASSOCIATED REGULATIONS

Does the bill direct, or will the bill result in, regulation changes adopted by your agency? No
If yes, by what date are the regulations to be adopted, amended or repealed?

Why this fiscal note differs from previous version:

Not applicable, initial version.

Prepared By: Janey Hovenden, Director Phone: (907)465-2536
Division: Corporations, Business and Professional Licensing Date: 02/19/2016 10:35 AM
Approved By: Catherine Reardon, Director Date: 02/19/16
Agency: Division of Administrative Services, DCCED

FISCAL NOTE ANALYSIS

STATE OF ALASKA
2016 LEGISLATIVE SESSION

BILL NO. SB 113

Analysis

SB113 would provide certain immunities to prescribing physicians, manufacturers, and distributors acting in good faith to allow terminally ill patients who have exhausted other available treatments faster access to experimental drugs, without waiting for federal approval.

This legislation prohibits disciplinary action against physicians by the State Medical Board for prescribing, dispensing or administering an investigational drug, biological product, or device to terminally ill patients who have considered all other treatment options approved by the FDA. In addition, it prevents hospitals and health facilities from restricting the use of investigational drugs as provided.

This legislation establishes immunity for physicians, manufacturers, and distributors in the case of injury or death of a terminally ill patient from the use of an investigational drug, biological product or device, provided informed consent was obtained from the patient and notice of immunity was given in advance.

This legislation amends the statute limiting the sale and distribution of new drugs so as not to apply to physicians prescribing or administering investigational drugs under the conditions established in Section 1.

The Division of Corporations, Business, and Professional Licensing does not anticipate fiscal impact from this legislation.